RT Journal Article
SR Electronic
T1 Determinants of Survival of Ablation Treatment for Portal Vein Tumor Thrombus in Patients With Hepatocellular Carcinoma
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 2501
OP 2505
DO 10.21873/invivo.13721
VO 38
IS 5
A1 ISHIKAWA, TORU
A1 SATO, RYO
A1 JIMBO, RYO
A1 KOBAYASHI, YUJI
A1 SATO, TOSHIFUMI
A1 IWANAGA, AKITO
A1 SANO, TOMOE
A1 YOKOYAMA, JUNJI
A1 HONMA, TERASU
YR 2024
UL http://iv.iiarjournals.org/content/38/5/2501.abstract
AB Background/Aim: The prognosis of hepatocellular carcinoma (HCC) complicated with portal vein tumor thrombus (PVTT) is extremely poor. This study investigated whether local ablation—a curative treatment similar to resection—could improve the prognosis of patients with Child-Pugh B/C PVTT. Patients and Methods: Between January 2020 and December 2023, 25 patients with Child-Pugh B/C PVTT HCC were enrolled, and their overall survival with radiofrequency ablation treatment and the associated drivers were investigated. Results: Overall survival (median 282 days) differed between the group treated with transarterial chemoembolization (TACE, 285 days) and the group without it (159 days, p=0.0151). The median survival in the esophagogastric variceal exacerbation group (120.5 days) was shorter than that in the non-exacerbation group (284.0 days, p=0.00964). In multivariate analysis, concomitant TACE had a hazard ratio (HR) of 0.121 (p=0.0097), and the exacerbation of esophagogastric varices had a HR of 6.761 (p=0.01). Conclusion: Local ablation for PVTT may promote patient survival specifically by inhibiting the exacerbation of portal hypertension in patients with hepatocellular carcinoma.